Compare · CAI vs ILMN
CAI vs ILMN
Side-by-side comparison of Caris Life Sciences Inc. (CAI) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAI and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $33.97B, about 35.0x CAI ($971.9M).
- CAI has been more active in the news (16 items in the past 4 weeks vs 11 for ILMN).
- ILMN has more recent analyst coverage (25 ratings vs 15 for CAI).
- Company
- Caris Life Sciences Inc.
- Illumina Inc.
- Price
- $28.00+7.18%
- $225.01+0.76%
- Market cap
- $971.9M
- $33.97B
- 1M return
- +79.14%
- -
- 1Y return
- -27.03%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- 2000
- News (4w)
- 16
- 11
- Recent ratings
- 15
- 25
Caris Life Sciences Inc.
CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost equivalent units. The company was formerly known as Container Applications International, Inc. and changed its name to CAI International, Inc. in February 2007. CAI International, Inc. was incorporated in 1989 and is headquartered in San Francisco, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CAI
- SEC Form 144 filed by Caris Life Sciences Inc.
- Director Castleman Peter M was granted 13,192 shares, increasing direct ownership by 82% to 29,321 units (SEC Form 4)
- Director Phillips T Danny was granted 13,192 shares, increasing direct ownership by 11% to 133,060 units (SEC Form 4)
- Director Minor Lloyd was granted 13,192 shares, increasing direct ownership by 71% to 31,813 units (SEC Form 4)
- Director Gilliam Joseph E was granted 13,192 shares, increasing direct ownership by 82% to 29,321 units (SEC Form 4)
- Director Fredrickson David Paul was granted 13,192 shares, increasing direct ownership by 71% to 31,813 units (SEC Form 4)
- Director Vacirca Jeff L was granted 13,192 shares, increasing direct ownership by 27% to 62,863 units (SEC Form 4)
- Director Johansen Laura I was granted 13,192 shares, increasing direct ownership by 4% to 343,897 units (SEC Form 4)
- Director Halbert Jon was granted 13,192 shares, increasing direct ownership by 11% to 131,813 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.
Latest ILMN
- Director Meister Keith A. sold $145,556,398 worth of shares (679,574 units at $214.19) (SEC Form 4)
- SVP, Strategy/Corp Development Wedel Christensen Jakob sold $197,840 worth of shares (1,033 units at $191.52), decreasing direct ownership by 7% to 14,023 units (SEC Form 4)
- SEC Form 8-K filed by Illumina Inc.
- Illumina Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 8-K filed by Illumina Inc.
- SEC Form 3 filed by new insider Coletti Julie Ann
- SEC Form FWP filed by Illumina Inc.
- Chief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)
- Illumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Director Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)